A 42-year-old nulliparous woman presents with a 3-year history of progressive menorrhagia, dysmenorrhoea, and lower abdominal distension. She reports passage of clots and has required two transfusions in the past year. Pelvic examination reveals a firm, irregular, massively enlarged uterus (approximately 16 weeks size). Ultrasound shows multiple intramural and subserosal fibroids, the largest measuring 6 cm, with significant distortion of the endometrial cavity. Her haemoglobin is 8.1 g/dL and ferritin is 12 ng/mL. She has completed her family and is open to definitive surgery. What is the most appropriate management?

Explanation

## Management of Severe Symptomatic Fibroids in a Woman Completing Family ### Clinical Context This patient has: - **Severe menorrhagia** with transfusion-dependent anaemia (Hb 8.1 g/dL) - **Massive uterine enlargement** (16 weeks size) with multiple large fibroids - **Completed family** — fertility preservation is NOT a priority - **Significant endometrial cavity distortion** — medical management unlikely to succeed ### Why GnRH Agonist + Hysterectomy Is Optimal **Key Point:** In women with completed family, severe symptomatic fibroids, and massive uterine enlargement, GnRH agonist pretreatment followed by hysterectomy is the gold standard. **High-Yield:** GnRH agonist pretreatment (3–6 months) provides: - Fibroid shrinkage (30–50% volume reduction) - Correction of anaemia (reduced menstrual blood loss) - Reduced operative blood loss during hysterectomy - Reduced need for blood transfusion perioperatively - Easier surgical dissection and lower morbidity - Potential conversion of abdominal hysterectomy to vaginal or laparoscopic route ### Why Other Options Are Suboptimal | Option | Rationale for Rejection | |--------|------------------------| | **LNG-IUD alone** | Unlikely to control menorrhagia in massive fibroids with endometrial cavity distortion; patient is transfusion-dependent and needs definitive therapy | | **Hysteroscopic myomectomy only** | Addresses only submucosal component; does not treat large intramural/subserosal fibroids; inadequate for massive uterine enlargement | | **Uterine artery embolisation (UAE)** | Effective for fibroid symptom control but not definitive; requires long-term follow-up; risk of fibroid regrowth; not ideal when definitive surgery is acceptable | ### Clinical Pearl **Preoperative GnRH agonist benefits in massive fibroids:** - Reduces operative time by 20–30 minutes - Decreases blood loss by 30–40% - Reduces transfusion rate from 30% to <10% - Allows safer conversion to minimally invasive routes - Corrects iron-deficiency anaemia before surgery ### Treatment Algorithm for Massive Fibroids in Non-Fertility-Seeking Women ```mermaid flowchart TD A[Massive fibroids + completed family]:::outcome --> B{Severe symptoms + anaemia?}:::decision B -->|Yes| C[GnRH agonist 3-6 months]:::action C --> D[Correct anaemia + fibroid shrinkage]:::outcome D --> E[Hysterectomy]:::action E --> F[Definitive cure]:::outcome B -->|No| G{Fertility desired?}:::decision G -->|Yes| H[Medical management or myomectomy]:::action G -->|No| I[Hysterectomy ± GnRH pretreatment]:::action ``` **Warning:** Do NOT use GnRH agonists as monotherapy for >6 months due to hypoestrogenia-related bone loss and vasomotor symptoms. Always plan definitive surgery within 3–6 months of initiation. **Mnemonic:** **GNRH-PREP** = GnRH agonist Preoperative Reduction Enhances Perioperative safety.